Terminal
Stocks
Spotlight
Research

Stocks
Healthcare
NASDAQ
LGND

Market Cap: $5.7B

LI

Ligand Pharmaceuticals Incorporated

LGND

NASDAQ (NASDAQ Global Market)USD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive Patents Earnings Surprise

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Financials

Profitability

Gross Profit Margin98.58%

EBITDA Margin94.22%

EBIT Margin82.50%

Pre-tax Margin81.90%

Net Profit Margin67.88%

Earnings Yield3.46%

Valuation Multiples

Price / Book5.90

Price / Sales19.62

Price / Earnings28.42

PEG0.03

Forward PEG0.95

EV / Sales20.05

EV / EBITDA21.28

EV / Operating Cash Flow44.25

EV / Free Cash Flow44.35

Price / Free Cash Flow43.40

Price / Operating Cash Flow43.35

Cash Flow & Capital

Free Cash Flow / Share$6.55

Operating Cash Flow / Share$6.56

Free Cash Flow Yield2.30%

Capex / Revenue0.10%

Capex / Operating Cash Flow0.21%

Capex / Depreciation0.01

Stock Compensation / Revenue18.33%

Dividend Payout Ratio0.00%

Dividend Yield0.00%

Liquidity & Leverage

Current Ratio31.18

Quick Ratio30.96

Cash Ratio21.54

Debt / Assets0.52

Debt / Capital0.54

Debt / Equity1.17

Long-Term Debt / Capital0.54

Debt / Market Cap19.76%

Net Debt / EBITDA0.46

Solvency Ratio0.19

Financial Leverage2.26

Efficiency & Working Capital

Asset Turnover0.13

Fixed Asset Turnover45.12

Inventory Turnover0.40

Receivables Turnover4.16

Payables Turnover0.44

Days Sales Outstanding87.84

Days Inventory Outstanding909.11

Days Payables Outstanding833.11

Operating Cycle996.95

Cash Conversion Cycle163.84

Working Capital Turnover0.26

Returns & Quality

Return on Equity20.06%

Return on Assets9.02%

Return on Invested Capital3.91%

ROCE4.72%

Return on Tangible Assets10.52%

Operating Return on Assets5.43%

Income Quality0.67

Tax Burden0.83

Interest Burden0.99

Balance Sheet & Intrinsic Metrics

Enterprise Value$5.83B

Invested Capital$1.73B

Working Capital$1.41B

Tangible Asset Value$656.73M

Net Current Asset Value$238.76M

Graham Number$103.28

Graham Net-Net$9.82

Book Value / Share$48.22

Tangible Book Value / Share$32.73

Cash / Share$67.67

Financial Health Scores

Piotroski Score5

Altman Z-Score4.50

Revenue$290.54M

EBIT$239.71M

Market Cap$5.8B

Working Capital$1.41B

Retained Earnings$583.25M

Total Assets$2.19B

Total Liabilities$1.22B